Which somatic approach has the most evidence for preventing Post-Traumatic Stress Disorder (PTSD) symptoms?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Hydrocortisone Has the Most Evidence for Preventing PTSD Symptoms

Among the somatic approaches listed, hydrocortisone (Option B) has moderate quality evidence supporting its efficacy in preventing PTSD onset, distinguishing it from other pharmacological agents that show limited benefit for prevention. 1

Evidence Hierarchy for PTSD Prevention

Hydrocortisone: The Strongest Evidence

  • Hydrocortisone demonstrates a risk ratio of 0.17 (95% CI 0.05-0.56) for preventing PTSD onset across four trials with 165 participants, indicating that between 7 and 13 patients need treatment to prevent one case of PTSD. 2
  • This represents moderate quality evidence, with three of four randomized controlled trials showing hydrocortisone was more effective than placebo in reducing PTSD symptoms after a median of 4.5 months post-trauma. 2
  • The American Psychiatric Association and International Society for Traumatic Stress Studies distinguish hydrocortisone from other agents due to this moderate quality evidence supporting prevention efficacy. 1

Propranolol: Limited and Inconsistent Evidence

  • Propranolol shows low quality evidence for preventing PTSD onset, with a risk ratio of 0.62 (95% CI 0.24-1.59, p=0.32) across three trials with 118 participants—this confidence interval crosses 1.0, indicating no statistically significant benefit. 2
  • While one small 2002 pilot study (n=41) suggested potential benefit with fewer physiologic responders during trauma script imagery at 3 months (0 of 8 propranolol vs 6 of 14 placebo patients), this has not been consistently replicated. 3
  • A 2021 randomized trial found no treatment difference between propranolol and placebo for PTSD symptoms, with both groups showing similar 34-39% symptom reduction. 4
  • The guideline literature consistently notes that early propranolol administration has been found to be of limited benefit overall for preventing PTSD symptoms. 1

SSRIs: Treatment, Not Prevention

  • SSRIs (sertraline and paroxetine) have FDA indication for treating established chronic PTSD, but there is no evidence supporting their use for preventing PTSD onset. 1
  • The single trial of escitalopram for prevention demonstrated no evidence of superiority over placebo. 2

Other Agents Without Prevention Evidence

  • Benzodiazepines show harmful effects, with 63% of patients receiving benzodiazepines developing PTSD at 6 months compared to only 23% receiving placebo. 5
  • Temazepam and gabapentin single trials showed no evidence of preventing PTSD onset. 2
  • Ketamine and albuterol are not mentioned in guideline literature for PTSD prevention. 5, 1

Critical Caveats

  • All pharmacological prevention strategies have limited overall benefit, with secondary prevention (cognitive-behavioral interventions delivered post-trauma) having more robust evidence than medication approaches. 1, 6
  • The hydrocortisone evidence base, while the strongest among medications, still derives from small studies with multiple methodological limitations, including high risk of bias in seven of nine included trials. 2
  • Drop-outs due to treatment-emergent side effects were low for all tested agents where reported. 2

Answer: B. Hydrocortisone

References

Guideline

Preventing PTSD Symptoms with Pharmacological Interventions

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Pharmacological interventions for preventing post-traumatic stress disorder (PTSD).

The Cochrane database of systematic reviews, 2014

Research

Traumatic memory reactivation with or without propranolol for PTSD and comorbid MD symptoms: a randomised clinical trial.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2021

Guideline

Treatment of Post-Traumatic Stress Disorder (PTSD)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Primary Prevention of PTSD: Evidence for Pre-Deployment Strategies

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.